Intellia Therapeutics
Market cap $1.37B 140.4M shares (10-Q, Oct 30, 2026) × $9.78 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- MAGNITUDE ATTR-CM corporate update2H 2026 / early 2027MAGNITUDE ATTR-CM corporate update, 2H 2026 / early 2027, notable
- lonvo-z commercial launch1H 2027lonvo-z commercial launch, 1H 2027, routine
- lonvo-z HAE PDUFA dateMar 10, 2027lonvo-z HAE PDUFA date, Mar 10, 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
nexiguran ziclumeran
nex-z · NTLA-2001nex-z
nexiguran ziclumeran · NTLA-2001Capital (as filed)
- Cash
- $156M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $318M Sep 30, 2026
- Long-term investments
- $141M Sep 30, 2026
- Operating cash flow
- −$85.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $615M cash, runway at least into 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-13 UPDATE: Intellia Therapeutics (NTLA) - Four Years, No Crack 🔒 Paid
- 2026-11-06 UPDATE: Intellia Therapeutics (NTLA) - No Panel, and a Sell-Off Anyway 🔒 Paid
- 2026-09-08 UPDATE: Intellia Therapeutics (NTLA) - The Clock Has a Date on It Now 🔒 Paid
- 2026-09-04 UPDATE: Intellia Therapeutics (NTLA) - They Mortgaged the Codebase
- 2026-08-07 UPDATE: Intellia Therapeutics (NTLA) - They Found the Bug 🔒 Paid
- 2026-06-15 UPDATE: Intellia Therapeutics (NTLA) - The HAELO Receipts Land in NEJM 🔒 Paid
- 2026-05-12 UPDATE: Intellia Therapeutics (NTLA) - The MAGNITUDE Hold Quietly Lifted 🔒 Paid
- 2026-04-30 UPDATE: Intellia Therapeutics (NTLA) - The Offering Priced at $10.75 🔒 Paid
- 2026-04-28 UPDATE: Intellia Therapeutics (NTLA) - The Code Compiled Clean 🔒 Paid
- 2026-04-27 UPDATE: Intellia Therapeutics (NTLA) - The Clock Is Set for Monday Morning 🔒 Paid
- 2026-03-05 Intellia Therapeutics (NTLA) - Scientific Deep Dive for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Intellia Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-03-05 Watch Intellia Therapeutics (NTLA) - Scientific Deep Dive for Lead and Pipeline Products Brilliant first-in-class CRISPR science is burdened by an active FDA clinical hold on the ATTR-CM program and a contested IP landscape, making entry premature.
- 2026-04-27 Watch UPDATE: Intellia Therapeutics (NTLA) - The Clock Is Set for Monday Morning Maintaining Watch List stance ahead of the binary HAELO Phase 3 readout; advising existing holders to hold and non-holders to avoid chasing the print.
- 2026-04-28 Buy core UPDATE: Intellia Therapeutics (NTLA) - The Code Compiled Clean HAELO Phase 3 hit primary endpoint with 87% attack reduction and zero SAEs, retiring clinical risk on lonvo-z and initiating a rolling BLA; buy the offering price once it prices, not the print.
- 2026-04-30 Buy core UPDATE: Intellia Therapeutics (NTLA) - The Offering Priced at $10.75 Offering priced at $10.75 sets the entry; lonvo-z BLA on the clock with runway extended to 2028, while platform remains on hold pending MAGNITUDE resolution.
- 2026-05-12 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - The MAGNITUDE Hold Quietly Lifted FDA lifting the MAGNITUDE ATTR-CM clinical hold closes the single largest gap in the bull thesis, justifying an upgrade from platform HOLD to Speculative Buy on the full platform, though IP risks and unresolved safety questions remain.
- 2026-06-15 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - The HAELO Receipts Land in NEJM Full HAELO dataset published in NEJM confirms all secondary endpoints with margin, reinforcing the lonvo-z BLA narrative; platform speculative buy maintained as MAGNITUDE safety data remains the next true binary.
- 2026-08-07 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - They Found the Bug Retrospective HLA allele association provides a mechanistic, screenable explanation for nex-z hepatotoxicity, de-risking but not resolving the platform safety question; speculative buy maintained with the stock 25% lower than the June update.
- 2026-09-04 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - They Mortgaged the Codebase Non-dilutive $400M OrbiMed debt facility funds the launch without new equity issuance, but pledging contested IP as first-lien collateral changes the risk composition; speculative buy maintained.
- 2026-09-08 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - The Clock Has a Date on It Now FDA accepted the lonvo-z BLA with priority review and set a March 10, 2027 PDUFA date, converting an open-ended regulatory wait into a six-month countdown and unlocking the OrbiMed approval tranche.
- 2026-11-06 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - No Panel, and a Sell-Off Anyway FDA confirmed no advisory committee planned for lonvo-z, MAGNITUDE-2 fully enrolled, and launch narrowed to Q1 2027; speculative buy maintained as the regulatory path is cleaner despite the stock selling off.
- 2026-11-13 Speculative buy speculative UPDATE: Intellia Therapeutics (NTLA) - Four Years, No Crack Phase 1/2 data show lonvo-z kallikrein knockdown maintained for up to four years with no waning, answering the durability question ahead of the March 10 PDUFA; speculative buy maintained with the stock cheaper than at prior updates.
- Long call · opened Apr 28, 2026 at $13.20 · -25.9% vs XBI +10.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (5 quotes from 5 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Founded 2014 WORLD’S FIRST Patient dosed 2020 WORLD’S FIRST In vivo gene editing clinical data 2021 WORLD’S FIRST Ph3 clinical trial initiated 2024 WORLD’S FIRST Fully enrolled Ph3 clinical trial 2025 WORLD’S FIRST Presentation of Ph3 clinical data 2026 MARCH 10 Potential approval 2027 Lonvo-z BLA Under Review BLA ACCEPTED BY FDA REGULATORY REVIEW Priority review granted PDUFA GOAL DATE MARCH 10, 2027 SEPTEMBER 3, 2026 FDA COMMUNICATION: “We are not currently planning to hold an advisory committee to discuss this application.”
matched to lonvo-z (HAE) · regulatory decision
-
-
-
“On September 8, 2026, the Company announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Biologics License Application (“BLA”) for lonvo-z and granted the BLA Priority Review with a Prescription Drug User Fee Act (“PDUFA”) target action date of March 10, 2027.”
matched to lonvo-z (HAE) · regulatory decision
-
-
-
“In September, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027.”
matched to lonvo-z (HAE) · regulatory decision
-
-
-
“Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy and the only one-time HAE treatment, if approved CAMBRIDGE, Mass., September 8, 2026 -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.”
matched to lonvo-z · regulatory submission / matched to lonvo-z (HAE) · regulatory decision
-
-
-
“In April 2026, the Company reported positive topline data from the global Phase 3 HAELO clinical trial of lonvo-z in HAE, and preparations are underway for the planned commercial launch of lonvo-z in the first half of 2027, if approved.”
matched to lonvo-z · regulatory submission / matched to nex-z (ATTR-CM) · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (37)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 20268-K/ACurrent report (amended): Reg FD disclosure · EX-99.1
- Nov 12, 2026ReleaseIntellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateFour years of follow-up with zero waning: the lonvo-z durability data the FDA label depends on came in clean today, while the stock fell 7.5% — here's what readers need to know before the March 10 PDUFA.
- Nov 10, 2026ReleaseIntellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Nov 5, 2026ReleaseIntellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateQ3 earnings landed this morning with MAGNITUDE-2 enrollment complete (exceeding its target), a new CMO aboard, and a $127.5M net loss that includes a $10.4M non-cash investment writedown — the market sold the print −9.8%, likely misreading the headline; here's what actually changed and what didn't.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseIntellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
- Nov 3, 2026ReleaseIntellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
- Oct 29, 2026ReleaseIntellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
- Oct 13, 2026ReleaseIntellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
- Sep 8, 2026ReleaseIntellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)→ BD updateSummary on the 8-K
- Sep 8, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe FDA accepted Intellia's lonvo-z BLA with Priority Review and set a March 10, 2027 PDUFA date — the "upside surprise" catalyst I called in the September 4 update has now landed, putting the world's first in vivo CRISPR approval on a legal clock.
- Sep 4, 2026ReleaseIntellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference→ BD updateSummary on the 8-K
- Sep 4, 2026ReleaseIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million→ BD updateSummary on the 8-K
- Sep 4, 20268-KCurrent report: material agreement, debt / obligation, Reg FD disclosure · EX-99.1→ BD updateIntellia just closed a $400M non-dilutive debt facility with OrbiMed — structured so that the milestones unlocking the remaining $325M are exactly the lonvo-z catalysts the thesis has been tracking, but the security interest over all assets (including contested IP) introduces a new risk layer worth unpacking.
- Aug 6, 2026ReleaseIntellia Therapeutics Announces Second Quarter 2026 Financial Results and Business UpdatesBD extracted 1 program update from this document → NTLA pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → NTLA pipeline
- Jul 30, 2026ReleaseIntellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
- Jun 15, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 13, 2026ReleaseIntellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaBD extracted 1 program update from this document → NTLA pipeline
- Jun 10, 20268-KCurrent report: shareholder vote
- Jun 1, 2026ReleaseIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026BD extracted 1 program update from this document → NTLA pipeline
- May 11, 2026ReleasePresented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUD
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 202610-QQuarterly report
- May 5, 2026ReleaseCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing an
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Apr 30, 20268-KCurrent report: material agreement, results of operations
- Apr 29, 2026424B5Prospectus supplement (offering)
- Apr 27, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 27, 2026424B5Prospectus supplement (offering)
- Apr 10, 20268-KCurrent report: charter / bylaws / fiscal year
- Mar 2, 20268-KCurrent report: material agreement, Reg FD disclosure, other events · EX-99.1
- Mar 2, 2026424B5Prospectus supplement (offering)
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 30, 2026ARSAnnual report to shareholders
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 27, 2026SCHEDULE 13G/A13G amendment